The market for hormone replacement therapy (HRT) products is vast and largely untapped. Two new concepts in HRT, recently launched in the UK, are hoped to realise that market by giving women easier, more palatable options for therapy. There are also plenty more ideas in the pipeline. One of the recently launched products is ‘Tridestra’. It is the first HRT product to be taken in 91-day cycles, resulting in 4 periods of withdrawal bleeding per year, rather than 13. It is licensed for the treatment of menopausal symptoms in peri- and postmenopausal women, and the prevention of postmenopausal osteoporosis.